Pedro Gómez is the CEO and co-founder of Orbem, a Munich-based techbio company unlocking new applications for AI-powered imaging. Founded as a spin-out from the Technical University of Munich, Orbem has raised over >€50 million and built strategic partnerships across sectors including agriculture, health, and logistics. Pedro holds a PhD in Biomedical Imaging and Informatics and has led the company from academic research through product development, fundraising, and commercial deployment.

Orbem could have gone in a dozen directions.
Instead, they chose one.

Orbem began as an AI-powered imaging platform spun out of the Technical University of Munich. Interestingly, as part of its go-to-market strategy, it is now deployed in an industrial setting, scanning over 100 million eggs to date. But before scale came focus: choosing a first application, aligning around a strategic path, and building a roadmap that made sense to customers, regulators, and investors - without losing the ambition of the platform underneath it.

Pedro will take us inside the decisions that shaped his company’s first chapter:

• Why poultry first, and not a specific healthcare market

• Which risks they took on early - and which risks they left unresolved

• How they knew what was working, and what to ignore

• What alignment with his board actually looked like, and how they built it

Why this matters to you?

Our Strategy Month opens with Emma Tinsley, co-founder and CEO of Weatherden, who brings lessons from the therapeutic side - how to move from concept to proof-of-concept through integrated clinical, regulatory, and commercial thinking. Pedro’s session offers a complementary lens: the strategic path for founders building at the edge of science and engineering, where technical possibility exceeds resources and early choices shape everything that follows.